Synthes & Eli Lilly to co-develop osteoporosis drugs

By

Synthes and Lilly Sign Development and Collaboration Agreement (press release)
Synthes, Eli Lilly To Cooperate On Orthopedic Products (WSJ)
ZURICH (Dow Jones)--Swiss surgical implant maker Synthes Inc (SYST.VX) Thursday said it had signed an agreement with Eli Lilly and Co. (LLY) to license and co-develop orthopedic products.
The deal will focus on patients in surgical and orthopedic treatment, including those with osteoporosis and bone fractures, Synthes said.
Through the deal, Synthes will license early-stage compounds from Lilly for use within the orthopedic trauma, spine, craniomaxillofa...

Get access to full posts newsletters, trends, and market reports for only subscribe for $1/day.
Hit the SUBSCRIBE button at the top of the homepage.